504314 Sigma-AldrichBortezomib - CAS 179324-69-7 - Calbiochem
Bortezomib, CAS 179324-69-7, is a cell-permeable, selective, slowly reversible inhibitor of 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity.
More>> Bortezomib, CAS 179324-69-7, is a cell-permeable, selective, slowly reversible inhibitor of 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity. Less<<Synonyms: BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu, (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
179324-69-7 | C₁₉H₂₅BN₄O₄ |
Pricing & Availability
Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.04314.0001 |
|
Glass bottle | 5 mg |
|
— |
Description | |
---|---|
Overview | A cell-permeable dipeptidylboronate compound that selectively inhibits 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity (kinact/Ki = 38,000, 5,700, and <100 M-1s-1, respectively, in human 20S proteasome assays using 10 µM Suc-LLVY-AMC/Cat. No. 539142, 10 µM Z-LLE-AMC/Cat. No. 539141, or 50 µM Boc-LRR-AMC as substrate) via a covalent, slowly reversible manner, displaying much reduced potency against human chymotrypsin, cathepsin G, leukocyte elastase, and thrombin (Ki = 0.32, 0.63, 2.3, and 13 µM, respectively, vs. 620 nM using rabbit muscle 20S). A widely used inhibitor both in cultures in vitro and in animals in vivo. |
Catalogue Number | 504314 |
Brand Family | Calbiochem® |
Synonyms | BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu, (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid |
Product Information | |
---|---|
CAS number | 179324-69-7 |
Form | Off-white solid |
Hill Formula | C₁₉H₂₅BN₄O₄ |
Chemical formula | C₁₉H₂₅BN₄O₄ |
Hygroscopic | Hygroscopic |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ100 |
Biological Information | |
---|---|
Primary Target | 20S proteasome |
Purity | ≥98% by LC-MS |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.04314.0001 | 04055977263923 |
Documentation
Bortezomib - CAS 179324-69-7 - Calbiochem MSDS
Title |
---|
Bortezomib - CAS 179324-69-7 - Calbiochem Certificates of Analysis
Title | Lot Number |
---|---|
504314 |
References
Reference overview |
---|
Du, X.L, and Chen, Q. 2013. Acta Haematol. 129, 207. Tamatani, T., et al. 2013. Int. J. Oncol. 42, 935. Beck, P., et al. 2012. J. Biol. Chem. 393, 1101. Fang, H.T., et al. 2012. Proc. Natl. Acad. Sci. USA. 109, 2521. Chen, D., et al. 2011. Curr. Cancer Drug Targets 11, 239. Demo, S.D., et al. 2007. Cancer Res. 67, 6383. Adams, J., et al. 1999. Cancer Res. 59, 2615. Teicher, B.A., et al. 1999. Clin. Cancer Res. 5, 2638. Adams, J., et al. 1998. Bioorg. Med. Chem. Lett. 8, 333. |
Data Sheet | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
|